Scott James, MD, PhD
Assistant Attending – Medical Oncologist – CAR-T group Leader
Education
Immunology – University of Washington, MD, PhD
Fellowships
Hematology/Oncology - Memorial Sloan Kettering Cancer Center
Residencies
Internal Medicine - University of Washington
Board Certifications
Internal Medicine; Medical Oncology; Hematology
Biography
Scott James received his MD and PhD from the University of Washington in Seattle where he studied aspects of chimeric antigen receptor-mediated T cell targeting related to target antigen topology and tissue expression. He subsequently completed internal medicine residency at University of Washington and joined the MSKCC hematology/oncology program. Upon completing his fellowship at MSKCC, he joined the Bone Marrow Transplantation Service as faculty member.
Research
Chimeric antigen receptor-modified T cells have demonstrated clinical successes in B cell malignancies and are currently being evaluated in other malignancies targeting novel antigens. I am interested in synthetic biology approaches to modify T cell behavior and function with the goal of improving the clinical efficacy and tissue selectivity of adoptive cellular immunotherapy. I additionally am interested in the application of synthetic biology approaches, including chimeric antigen receptors, to improve graft vs. leukemia/lymphoma responses while decreasing graft vs. host responses in the transplant setting.
Funding
National Institute of Health - K08 Clinical Investigator Award (2020-2025)
Parker Institute for Cancer Immunotherapy - Parker Bridge Scholar (2017-2020)
Amy Strelzer Manasevit Research Program Award (2017-2020)
ASCO Young Investigator Award (2016-2017)
T32 institutional training grant (Academic year 2015 – 2016)